According to the Zhitong Financial App, the European Society for Medical Oncology (ESMO) annual meeting was held in Madrid, Spain, from October 23 to 27. Following the conference, J.P. Morgan released a research report on BioNTech (BNTX.US), beginning its summary with a straightforward conclusion: ESMO
This update, while positive, must be considered in light of the fact that the dataset is still in the early to mid-stage, and the timeline for key readouts—particularly for pumitamig, which is not expected until 2028–2030.
More than a year—without substantially changing our argument.” JPMorgan maintains its “neutral” rating on BioNTech with a price target of $92.
After communicating with the company following the meeting, the bank confirmed that BioNTech is focusing its efforts on combination therapies, with pumitamig serving as the primary backbone, typically combined with B7H3.
ADC. The minutes then individually discussed several key reports from the meeting.
Looking at it from a step back, JPMorgan’s stance is cautious: although a significant portion of BioNTech’s market capitalization is supported by cash balances, the firm is not eager to act at current levels until visibility into its pipeline becomes clearer.
Pumitamig: First Phase II data in second-line lung cancer shows significantly better results than the docetaxel benchmark.
ROSETTA Lung-107 is a global Phase II study evaluating pumitamig (PD-L1×VEGF-A)
Bispecific immunomodulator (developed in collaboration with Bristol Myers Squibb) combined with docetaxel for second-line non-small cell lung cancer (NSCLC) patients who have progressed after immunotherapy plus chemotherapy. In efficacy-evaluable patients, the confirmed objective response rate (cORR) was 37%, and the median progression-free survival (mPFS) was 6.9 months.
Months (data cutoff: July 10, 2026; median follow-up: 12.2 weeks).
Comparing against the benchmark is crucial: historical expectations for second-line docetaxel monotherapy are approximately a 13% ORR and 3.5–4 months mPFS. Responses were observed across all PD-L1
At the expression level; when analyzed separately, the cORR/unconfirmed ORR was 57% in squamous patients (n=7) and 30%/39% in non-squamous patients (n=23).
In terms of safety, J.P. Morgan considers acceptable: 18% of patients experienced treatment-related adverse events (TRAEs) of grade 3 or higher related to pumitamig, and 8% of patients discontinued treatment due to pumitamig-related
TRAE discontinuation; among the adverse events of concern, all bleeding events (16%) were grade 1, and no grade 3 or higher hypertension or proteinuria events occurred.
The conclusion of this line is not surprising—"We are not surprised to see greater benefit with the addition of pumitamig to docetaxel"—and it believes this second-line data further supports pumitamig.
Benefits in the global NSCLC population.
The timeline is a recurring constraint emphasized in this summary: Pumitamig is currently being evaluated in four global Phase III studies—including first-line NSCLC (ROSETTA Lung-02, data expected
(2029); first-line NSCLC with PD-L1 >50% (ROSETTA Lung-202, 2030 and beyond); unresectable stage III NSCLC
Consolidation after chemoradiotherapy (ROSETTA Lung-201, 2030 and beyond) and first-line small cell lung cancer (ROSETTA Lung-01, 2028).
BNT324 (B7H3 ADC): Combined data is more compelling; 6 mg/kg is the preferred dose
BNT324 is an antibody-drug conjugate (ADC) targeting B7-H3. The meeting presented updated Phase II monotherapy data in platinum-resistant ovarian cancer (PROC), along with data on its combination with pumitamig
Combine the initial data used for PROC.
The combination regimen demonstrated a compelling response rate: cORR of 71% (including 2 pending responses), with a median follow-up of 6.5 months (data cutoff: September 4, 2026).
Day, n=31).
Regarding monotherapy, the 6 mg/kg dose administered every three weeks is viewed by J.P. Morgan as the preferred regimen—based on communications with the company and the fact that this dose is the only one with data comparable to pumitamig
Combined data." At this dose, the cORR in 16 patients was 50% (unconfirmed ORR 62.5%), with a median duration of response of 6.9 months and mPFS of 8.3 months.
Month. The efficacy indicators for the 9 mg/kg every three weeks regimen were higher, but toxicity was significantly greater—35% or higher TRAEs occurred in 81% of patients in the 9 mg/kg group compared to 44% in the 6 mg group.
The conclusion is that BNT324 demonstrates promising characteristics both as a monotherapy and in combination; the monotherapy data is competitive, but following discussions with the company, J.P. Morgan believes BNT324’s priority lies in combination with
pumitamig joined.
Pumitamig + BNT324: Broad tumor-type early activity, with liver cancer data receiving the most attention
This global phase II trial announced results for pumitamig + BNT324.
The initial results across multiple solid tumors build upon the combined data previously presented at the World Conference on Lung Cancer (WCLC). ESMO
The report added early anti-tumor activity data for head and neck cancer, melanoma, liver cancer, cervical cancer, and platinum-resistant ovarian cancer.
The follow-up periods for the five tumor types ranged from 4.8 to 7.7 months; encouragingly, in patients previously treated with immunotherapy and/or Avastin (bevacizumab), the unconfirmed ORR was comparable to the confirmed ORR.
Similar to the general population. Hepatocellular carcinoma (HCC) and platinum-resistant ovarian cancer data received special attention in the report: among 21 HCC patients (median number of prior treatment lines was 2, with 19 having previously received
IO/bevacizumab combination: unconfirmed ORR/ORR was 43%/38%. Safety was manageable, with no dose-limiting toxicities (DLTs), and the profile was consistent with the known characteristics of each agent.
Gotistobart: Melanoma is no longer the priority; focus has shifted to Phase III head-to-head.
BioNTech also announced gotistobart in combination with pembrolizumab for previously treated patients with CTLA-4 and PD-(L)1.
Longer follow-up data from phase I/II study in recurrent/refractory melanoma: cORR/mPFS was 18%/2.6 months in the 3 mg/kg group (n=22) and for the 6 mg/kg group (n=27):
22% per 2.1 months.
Although the ORR and mPFS were similar between the two groups, the median overall survival was highly variable: 28 months for the 3 mg/kg group (follow-up of 33 months) and 11 months for the 6 mg/kg group (follow-up of
41 months).
After communicating with the company, JPMorgan Chase clarified: melanoma (post-IO treatment) is not gotistobart.
Priority direction. The company emphasized the Phase III head-to-head study comparing gotistobart monotherapy with docetaxel for second-line squamous cell carcinoma.
NSCLC, with overall survival as the primary endpoint; top-line data expected to be released this year.
Valuation and Position
This report does not adjust the rating or target price. JPMorgan maintains a "Neutral" rating and a target price of $92, implying approximately 5.9% upside from the current price of $86.86.
The upside potential—on the more conservative end among institutions covering the stock. The bank’s wait-and-see rationale does not stem from valuation itself, but from timing: key catalysts for core assets are concentrated between 2028 and 2030.
years, while current data are mostly early- to mid-stage results from small samples with short follow-up periods.
JPMorgan also pointed out a structural fact: BioNTech
A significant portion of the market cap is supported by cash balances—this provides some downside cushion but also means the stock is more dependent on the execution of future pipelines; the firm has chosen not to act prematurely until data becomes clearer. It should be noted that this transcript does not separately list upside/downside risks nor provide valuation methodology parameters (such as
DCF, WACC, etc.), in meeting minutes format, not a complete rating report.